Clinical Trial Update: A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma [Phase 1]

View source ↗

Summary

A Phase 1b open-label dose-escalation study of PLX3397 in combination with vemurafenib in V600-mutated BRAF melanoma has been terminated; results were posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Metastatic Melanoma That Has Not Been Previously Treated with Selective Braf Inhibitor
• V600-mutated Braf Metastatic Melanoma
• V600-mutated Braf Unresectable Melanoma

Drugs mentioned

• PLX3397 (PLX3397)
• Vemurafenib (vemurafenib)

Snippet

Sponsor: Daiichi Sankyo | Conditions: V600-mutated BRAF Unresectable Melanoma, V600-mutated BRAF Metastatic Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2020-05-28